US Department of Homeland Security, Customs and Border Protection, Selects JEOL Mass Spectrometers for Five Labs
JEOL USA, INC., a wholly owned subsidiary of JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi), has been awarded a major contract by the US Department of Homeland Security Customs and Border Protection (DHS – CBP) for five JEOL AccuTOF™ LC-plus 4G Time-of-Flight Mass Spectrometers equipped with DART™ (Direct Analysis in Real Time) ion sources. These instruments will enhance the analytical capabilities of five US Customs and Border Protection laboratories across the country. Three additional labs already installed the AccuTOF™ with DART™ in recent years, bringing the total usage to eight across the continental U.S. and Puerto Rico.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005874/en/
DART(TM) Direct Analysis in Real Time (Photo: Business Wire)
The AccuTOF™ systems with DART™ will be used by CBP scientists as a non-destructive, rapid means to analyze many types of forensic samples including drugs, suspected controlled substances, unknown substances, and general organic materials. The AccuTOF™ systems with DART™ will also allow the laboratories to quickly screen imported merchandise entering the United States that may violate Antidumping and Countervailing Duty Orders.
The AccuTOF™ mass spectrometer with DART™ allows the user to immediately determine chemical composition and produce high-resolution, accurate mass spectra by simply placing a sample in its native form between the DART™ ion source and the AccuTOF™ mass spectrometer inlet. Little to no sample preparation is required, unlike traditional analysis with mass spectrometry.
The DART™ was invented at JEOL USA by Cody and Laramee specifically for integration with the AccuTOF™ and this proven technology is used routinely by many crime and forensics labs for investigations or screening.
"We are very gratified to be supporting this Federal Government Agency with JEOL’s AccuTOF™-DART™ mass spec technology, which is ideal for their applications where fast answers and exact identification of a drug, unknown substances, or imported materials including foods and food additives, and even the origin of petroleum products are needed," said Michael Frey, Ph.D., JEOL USA Analytical Instruments Product Manager. “We believe the specialized ability to rapidly identify or confirm identification of samples without alteration will greatly assist the US DHS in their efforts to track the entry of illegal substances into the United States.”
Product information
DART™ Direct Analysis in Real Time
https://www.jeol.co.jp/en/products/detail/DART.html
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005874/en/
Contact information
JEOL USA, INC.
Pamela Mansfield
pmansfield@jeol.com
https://www.jeolusa.com/CONTACT-US/Find-a-Local-Sales-Rep/ESR-NMR-Mass-Spectrometry
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 14:00:00 EET | Press release
Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even greater value to our clients,” said Manuel Mateos, CEO of CMC Medical Devices. “Our sha
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 14:00:00 EET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 14:00:00 EET | Press release
Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Founder of Armis: “This round marks another defining moment in our journey to build a category-defining cybersecurity company. Our growth proves that organizations are embracing a unified, exposu
Compass Pathways to Participate in Stifel 2025 Healthcare Conference5.11.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP36
Xiid Launches Elite Advisory Board, Enlists Rachel Higham to Help Drive Next Phase of Growth5.11.2025 13:00:00 EET | Press release
Xiid Corp., which is revolutionizing cyber defense with zero knowledge networking, today announced it has assembled a distinguished advisory board and added Rachel Higham to this circle of trusted advisors. Formerly Marks & Spencer’s chief digital and technology officer, Higham will serve as a special advisor and consultant, leading Xiid’s go-to-market strategy with hyperscalers, colocation companies and telecom services providers. “Rachel contributes valuable perspective and experience,” said Xiid CEO Steve Visconti. “Now the new Xiid Advisory Board – which already includes global industry leaders with deep roots at such companies as Alcatel, Capgemini, Deloitte, Microsoft and Vodafone – is even stronger.” Higham learned of Xiid’s unique approach during her time with Marks & Spencer. In addition to her experience with the multinational retailer, she served as WPP’s CIO, BT’s managing director of IT and MD Asia and Vodafone’s head of cloud and infrastructure centre of excellence. “Xiid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom